Apotex wins Canadian approval for Apo-Semaglutide
Health Canada approved Apotex's Apo-Semaglutide Injection on May 1, 2026, the second generic Ozempic cleared in Canada in three days — but US generics still wait on patents.
Apotex said on 1 May 2026 that Health Canada had approved its Apo-Semaglutide Injection, a generic version of Novo Nordisk's Ozempic (semaglutide) [1]. The clearance came three days after Dr. Reddy's Laboratories announced on 29 April 2026 that it was the first company to win Health Canada approval for a generic semaglutide injection [1].
Apotex's approval covers two prefilled pen formats: a pen delivering 0.25 mg or 0.5 mg doses (containing 2 mg of semaglutide at 0.68 mg/mL) and a pen delivering 1 mg doses (containing 4 mg of semaglutide at 1.34 mg/mL) [1]. Apotex developed the product through a strategic partnership with Orbicular Pharmaceutical Technologies, a company headquartered in India [1]. Apotex described itself as the first Canadian-based global pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic [1].
The Dr. Reddy's approval, announced two days earlier, was for generic semaglutide injection for the treatment of type 2 diabetes in adults, and covers 2 mg/pen and 4 mg/pen formulations, both at 1.34 mg/mL [1]. Dr. Reddy's has not announced a launch date but said it has "launch plans underway" [1].
A pattern that started in India
Canada is the latest market to see semaglutide copies clear regulators. Several generic equivalents of Ozempic launched in India in March 2026, including one from Dr. Reddy's sold under the name Obeda [1]. In April 2026, Apotex secured the first US Food and Drug Administration tentative approval for its generic semaglutide abbreviated new drug application [1].
A tentative approval is not the same as a full US approval. It means the FDA has found the product meets its standards, but the company cannot sell it until Novo Nordisk's remaining US exclusivity and patents run out [1]. The source does not give a date for when that happens, so the timing of any US generic semaglutide launch is not yet known from this reporting.
Health Canada is reviewing a number of other generic semaglutide submissions, including applications from Teva, Aspen Pharmacare, Taro Pharmaceuticals and Sandoz [1]. Sandoz has been planning a 2026 generic semaglutide launch in Canada [1]. More Canadian approvals are expected in the coming weeks and months [1].
Why it matters for patients
For Americans, the immediate effect is none. These are Canadian approvals for the Canadian market, and nothing in this development changes what is available at a US pharmacy today. Ozempic and Wegovy (both semaglutide) remain brand-only in the United States.
What the news does signal is direction. Apotex now holds both a Canadian approval and a US tentative approval for its generic semaglutide [1]. That puts it in position to be among the first to launch in the US once Novo Nordisk's patents and exclusivity expire [1]. Generic competition typically follows a pattern in which prices fall as more approved sellers enter a market, and Canada is about to test that with at least two approved products and several more under review [1].
The approvals are also a reminder that the pens are not interchangeable across dose ranges. Apotex's two pens cover different dose steps — 0.25 mg and 0.5 mg in one, 1 mg in the other — and the higher 2 mg Ozempic dose is not listed in the approval described here [1]. Dr. Reddy's Canadian approval is specifically for type 2 diabetes in adults [1]; the sources do not say whether either product is approved in Canada for weight management, which in the US is a separate indication under the Wegovy brand.
Some US patients have looked north for lower prices. It is worth noting that the sources do not report any Canadian pricing, nor do they say when either generic will actually reach Canadian pharmacy shelves. Dr. Reddy's has not set a launch date [1], and no launch date was reported for Apotex either.
What happens next
- 29 April 2026: Dr. Reddy's announces first Health Canada approval for generic semaglutide injection [1].
- 1 May 2026: Apotex announces Health Canada approval for Apo-Semaglutide Injection [1].
- Coming weeks and months: Further Canadian generic semaglutide approvals expected, with pending applications from Teva, Aspen Pharmacare, Taro Pharmaceuticals and Sandoz [1].
- During 2026: Sandoz has been planning a Canadian generic semaglutide launch [1].
- US: Apotex's tentative FDA approval converts to a launch opportunity only after Novo Nordisk's exclusivity and patents expire; the date is not stated in the available sources [1].
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.